Matthew Mullarkey has left West Pharmaceutical Services by mutual consent. Mullarkey was West’s chief operating officer (COO). Following the departure Steven Ellers, West’s president and former COO, will defer his retirement, initially planned for 2010, to ensure managerial continuity.
Catalent Pharma Solutions has appointed Paul Burns to the newly created position of vice president (VP) of global sales. Burns will be responsible for developing Catalent’s global sales strategy, with particular emphasis on enhancing its current capabilities for all offerings.
Before joining Catalent Burns was CEO of New Jersey, US biotech Brighter Ideas. He also spent time at GE Healthcare and Emergency Cardiac Imaging and is a certified Six Sigma Green Belt.
Mark Lanfear has been appointed as VP of strategic alliances at Kforce Clinical Research, taking responsibility for leading strategic client relationship management and development efforts. Lanfear joined Kforce in 2006 as a regional manager.
Girindus America has appointed Marc Lemaître as its CEO. The company provides active pharmaceutical ingredient (API) related services and Lemaître will now lead its US operation, taking direct managerial responsibility for business development and R&D activities.
Lemaître began his industrial career at Rhone-Poulenc-Rorer, now part of Sanofi-Aventis, moving on to Eurogentec and later to Glen Research. Throughout his career he has focused on oligonucleotides, which Girindus manufacturers.